Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vectorite BiomedicalROCO:4170 +0.81%65 Current Ratio is 11.85 as of Dec. 2025, which is 27% above its 10-year median of 9.30. GuruFocus rates ROCO:4170 with a GF Score™ of 65/100 and a GF Value™ of NT$17.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Vectorite Biomedical ranks better than 81.72% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vectorite Biomedical's current ratio for the quarter that ended in Dec. 2025 was 11.85.
Vectorite Biomedical has a current ratio of 11.85. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Vectorite Biomedical's Current Ratio or its related term are showing as below:
ROCO:4170'
s Current Ratio Range Over the Past 10 Years
Min: 1.62 Med: 9.3 Max: 17.53
Current: 11.85
During the past 13 years, Vectorite Biomedical's highest Current Ratio was 17.53. The lowest was 1.62. And the median was 9.30.
ROCO:4170's Current Ratio is ranked better than 81.72% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs ROCO:4170: 11.85
Vectorite Biomedical (ROCO:4170) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Vectorite Biomedical Current Ratio Related Terms
Vectorite Biomedical Current Ratio Historical Data
* Premium members only.
The historical data trend for Vectorite Biomedical's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Vectorite Biomedical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's Current Ratio distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectorite Biomedical (ROCO:4170) has a Current Ratio of 11.85 as of Dec. 2025. This is 27% above median its historical median of 9.30. Over the past decade, Vectorite Biomedical's Current Ratio has ranged from 1.62 to 17.53. According to the industry distribution chart, Vectorite Biomedical ranks #258 out of 1411 companies in the Biotechnology industry, placing it in the top 18.3%.
Is Vectorite Biomedical's Current Ratio too high?
Vectorite Biomedical's current Current Ratio of 11.85 is 27% above median its 10-year median of 9.30. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 17.53. The Biotechnology industry median Current Ratio is 3.88. Vectorite Biomedical's value of 11.85 is 205.4% above this industry median. Based on the distribution chart, Vectorite Biomedical ranks #258 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vectorite Biomedical has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #258 out of 1411 companies for Current Ratio. This places Vectorite Biomedical in the top 18% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Vectorite Biomedical's value of 11.85 is 205.4% above this benchmark. Historically, Vectorite Biomedical's own Current Ratio has ranged from 1.62 to 17.53 over the past decade. While the company's 10-year median is 9.30 vs. the industry median of 3.88, Vectorite Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectorite Biomedical's current Current Ratio of 11.85 is 205.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectorite Biomedical's current Current Ratio is 11.85, which is 27% above median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.56, compared to a current price of NT$12.50 — trading 28.8% below its estimated fair value. The current Current Ratio is 11.85, which is 27% above median its 10-year median of 9.30 and 205.4% above the Biotechnology industry median of 3.88. Vectorite Biomedical's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Current Ratio is 11.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$12.50 is trading 28.8% below its estimated GF Value™ of NT$17.56.
GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.
Key valuation signals for ROCO:4170:
Current Ratio: 11.85 (27% above median its 10-year median of 9.30)
GF Value™: NT$17.56 vs. price of NT$12.50 (28.8% below fair value)
Industry Position: 205.4% above the Biotechnology median (#258 of 1411)
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
65GF Score
Get the complete analysis for ROCO:4170
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
